Niclosamide as an anti-obesity drug: an experimental study
- 155 Downloads
Niclosamide is a well-known anthelminthic drug that exert its effects at least in part through induction of mitochondrial uncoupling. The cycling of mitochondrial proton plays an essential role in regulation of basal metabolic rate, so modulation of mitochondrial uncoupling may be helpful approach to fight obesity.
To assess the anti-obesity effects of niclosamide on mice with induced obesity.
Materials and methods
Thirty male Albino mice, 8–10 weeks old, were divided randomly and equally in to three groups; Group 1 fed with standard diet, whereas both Groups 2 and 3 were fed with high fat diet (HFD). At 10 weeks, the studied groups continue in the same type of diet as before for another 4 weeks, but additionally both of Group1 and 2 received placebo treatment as normal control and high fat diet control respectively, whereas Group 3 received oral niclosamide (140 mg/kg/day) as treatment group. The anti-obesity effects of niclosamide were evaluated by testing its effects on food intake, bodyweight, glycemic indices, and lipid profile.
It was found that administration of niclosamide 140 mg/kg/day to HFD fed mice (Group3) for 4 weeks resulted in significant (P < 0.05) decline in the food intake and bodyweight of this group as compared with HFD control. Furthermore, niclosamide also resulted in significant (P < 0.05) lowering of the fasting blood glucose, fasting plasma insulin and improve insulin resistance. Likewise, niclosamide ameliorates the harmful effects of HFD on lipid profile by significant lowering of cholesterol, triglycerides, and LDL (P < 0.05).
Niclosamide has promising effects as an anti-obesity drug. It not just lowers bodyweight in mice, but, at the same time, it reverses metabolic disturbance induced by obesity.
KeywordsNiclosamide Obesity Mitochondrial uncoupling Lipid profile
- 2.Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al (2013) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 30;384(9945):766–781. doi:10.1016/S0140-6736(14)60460-8.CrossRefGoogle Scholar
- 9.Geloneze B, Tambascia MA (2006) Laboratorial evaluation and diagnosis of insulin resistance. Arq Bras Endocrinol Metabol 50(2):208215.Google Scholar
- 10.Rifai N, Warnick GR (2006) Measurement of lipids, lipoproteins, and apolipoproteins. In: Burtis CA, Ashwood ER, Bruns DE (eds) Tietz textbook of clinical chemistry and molecular diagnosis. 4th ed. Elsevier Saunders, St. Louis, pp 938–952Google Scholar
- 11.Mykkänen OT, Huotari A, Herzig KH, Dunlop TW, Mykkänen H, Kirjavainen PV (2014) Wild blueberries (Vaccinium myrtillus) alleviate inflammation and hypertension associated with developing obesity in mice fed with a high-fat diet. PLoS One 9(12):e114790. doi:10.1371/journal.pone.0114790 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Vernochet C, Mourier A, Bezy O, Macotela Y, Boucher J, Rardin MJ et al (2012) Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance. Cell Metab 16(6):765–776. doi:10.1016/j.cmet.2012.10.016 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Chun-Ching Shih, Jin-Bin Wu, Jia-Ying Jian, Cheng-Hsiu Lin, Hui-Ya Ho (2015) (–)-Epicatechin-3-O-β-d-allopyranoside from Davallia formosana, prevents diabetes and hyperlipidemia by regulation of glucose transporter 4 and AMP-activated protein kinase phosphorylation in high-fat-fed mice. Int J Mol Sci 16(10):24983–25001. doi:10.3390/ijms161024983 CrossRefPubMedPubMedCentralGoogle Scholar